3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
144
Sarcoma
19
Tumor-Agnostic
11
Genitourinary
11
Gynecologic
8
Thoracic
7
Other solid neoplasm
6
CNS
5
Gastrointestinal
4
Lymphoid
2
Head & Neck
2
Dermatologic
2
Conditions
Neoplasms
2
Lymphoma
2
Interventions
Rituximab
1371
Cyclophosphamide
1297
Vincristine
662
Doxorubicin
583
Etoposide
525
Prednisone
505
Cytarabine
481
fludarabine
462
Methotrexate
441
Dexamethasone
411
fludarabine phosphate
396
Lenalidomide
347
Filgrastim
342
Bendamustine Hydrochloride
274
Radiotherapy
266
venetoclax
255
ibrutinib
249
Peripheral Blood Stem Cell Transplantation
233
Melphalan
229
obinutuzumab
228
Granulocyte Colony-Stimulating Factor
212
Bortezomib
204
Gemcitabine
201
Busulfan
186
Whole-Body Irradiation
185
Mycophenolic Acid
174
Tacrolimus
164
Specimen Handling
161
Calcium Dobesilate
150
Magnetic Resonance Spectroscopy
149
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
eribulin
×
Lymphoid
×
Clear all
NCT02082626
2020-03-10
ERIBULIN
University of Oklahoma
Phase 1
Terminated
3 enrolled
NCT02171260
2019-01-15
BOLD 113
Eisai Inc.
Phase 1
Completed
23 enrolled
22 charts